stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) Return on equity
Sotera Health Company's return on equity over the twelve months to 30 September 2026 was 27.0%, up 11.6 percentage points from fiscal 2025 (15.4%). Over the past ten years it has ranged from −49.9% (fiscal 2022) to 41.4% (fiscal 2020); the current reading is higher than 75% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 15.4% | 4.97 |
| FY2024 | 10.5% | (2.42) |
| FY2023 | 12.9% | 62.76 |
| FY2022 | −49.9% | (72.35) |
| FY2021 | 22.5% | (18.94) |
| FY2020 | 41.4% | 34.40 |
| FY2019 | 7.00% | 5.04 |
| FY2018 | 1.96% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CDNA CareDx, Inc. compare | 33.0% |
| SHC Sotera Health Company | 27.0% |
| QGEN QIAGEN N.V. compare | 11.9% |
| VCYT Veracyte, Inc. compare | 9.43% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| RDNT RadNet, Inc. compare | −1.64% |
| NEO NeoGenomics, Inc. compare | −3.94% |
| GRAL GRAIL, Inc. compare | −17.3% |
| ADPT Adaptive Biotechnologies Corporation compare | −36.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement